Int J Thyroidol.  2024 May;17(1):21-29. 10.11106/ijt.2024.17.1.21.

Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part I. Initial Management of Differentiated Thyroid Cancers - Chapter 1. Preoperative Imaging and Diagnostic Evaluation in Thyroid Cancer 2024

• Lee JY
• Jo K
• Kang HC
• Kim SW
• Park YJ
• Bang JI
• Song YS
• Lee MK
• Lee EK
• Lim DJ
• Chung YJ
• Lee SW
• Na DG
• Korean Thyroid Association Guideline Committee on the Managements of Thyroid Nodule and Cancer

• KMID: 2556503
• DOI: http://doi.org/10.11106/ijt.2024.17.1.21

Abstract

The selected treatment for a nodule that is diagnosed as thyroid cancer is surgery. Imaging and blood tests are performed prior to surgery to determine the extent of the surgery. An Ultrasound (US) of the thyroid and neck should be performed to evaluate the size of the cancer, whether it is multifocal and has invaded surrounding tissues, and the status of the cervical lymph nodes (LNs). In addition to US, contrast-enhanced computed tomography may help detect cervical LN metastasis and evaluate patients suspected with invasive thyroid cancer. Generally, routine preoperative measurement of serum thyroglobulin and thyroglobulin antibody concentrations is not recommended. Integrated ¹⁸F-fluorodeoxyglucose positron-emission/computed tomography may be helpful either in patients with suspected lateral cervical LNs or distant metastasis or in patients with aggressive histology.

Keyword

Preoperative; Imaging; Ultrasound; Thyroid cancer; Guideline; Korean Thyroid Association

Reference

References

1. Ha EJ, Chung SR, Na DG, Ahn HS, Chung J, Lee JY, et al. 2021; 2021 Korean Thyroid Imaging Reporting and Data System and imaging-based management of thyroid nodules: Korean Society of Thyroid Radiology consensus statement and recommendations. Korean J Radiol. 22(12):2094–123. DOI: 10.3348/kjr.2021.0713. PMID: 34719893. PMCID: PMC8628155.

2. Hoang JK, Oldan JD, Mandel SJ, Policeni B, Agarwal V, et al. Expert Panel on Neurological Imaging. 2019; ACR Appropriateness Criteria((R)) thyroid disease. J Am Coll Radiol. 16(5S):S300–S14. DOI: 10.1016/j.jacr.2019.02.004. PMID: 31054756.

3. Lee JY, Baek JH, Ha EJ, Sung JY, Shin JH, Kim JH, et al. 2021; 2020 imaging guidelines for thyroid nodules and differentiated thyroid cancer: Korean Society of Thyroid Radiology. Korean J Radiol. 22(5):840–60. DOI: 10.3348/kjr.2020.0578. PMID: 33660459. PMCID: PMC8076832.

4. Ha EJ, Lim HK, Yoon JH, Baek JH, Do KH, Choi M, et al. 2018; Primary imaging test and appropriate biopsy methods for thyroid nodules: guidelines by Korean Society of Radiology and National Evidence-based Healthcare Collaborating Agency. Korean J Radiol. 19(4):623–31. DOI: 10.3348/kjr.2018.19.4.623. PMID: 29962869. PMCID: PMC6005947.

5. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2016; 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 26(1):1–133. DOI: 10.1089/thy.2015.0020. PMID: 26462967. PMCID: PMC4739132.

6. Takashima S, Takayama F, Wang J, Kobayashi S, Kadoya M. 2003; Using MR imaging to predict invasion of the recurrent laryngeal nerve by thyroid carcinoma. AJR Am J Roentgenol. 180(3):837–42. DOI: 10.2214/ajr.180.3.1800837. PMID: 12591706.

7. Wang J, Takashima S, Matsushita T, Takayama F, Kobayashi T, Kadoya M. 2003; Esophageal invasion by thyroid carcinomas: prediction using magnetic resonance imaging. J Comput Assist Tomogr. 27(1):18–25. DOI: 10.1097/00004728-200301000-00004. PMID: 12544237.

8. Wang JC, Takashima S, Takayama F, Kawakami S, Saito A, Matsushita T, et al. 2001; Tracheal invasion by thyroid carcinoma: prediction using MR imaging. AJR Am J Roentgenol. 177(4):929–36. DOI: 10.2214/ajr.177.4.1770929. PMID: 11566708.

9. Jeong SY, Chung SR, Baek JH, Choi YJ, Sung TY, Song DE, et al. 2022; Sonographic assessment of minor extrathyroidal extension of papillary thyroid microcarcinoma involving the posterior thyroid capsule. Eur Radiol. 32(9):6090–6. DOI: 10.1007/s00330-022-08765-9. PMID: 35380227.

10. Chung SR, Baek JH, Choi YJ, Sung TY, Song DE, Kim TY, et al. 2020; Sonographic assessment of the extent of extrathyroidal extension in thyroid cancer. Korean J Radiol. 21(10):1187–95. DOI: 10.3348/kjr.2019.0983. PMID: 32729261. PMCID: PMC7458864.

11. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. 2012; The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 22(11):1144–52. DOI: 10.1089/thy.2012.0043. PMID: 23083442.

12. Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, et al. 2003; Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 237(3):399–407. DOI: 10.1097/01.SLA.0000055273.58908.19. PMID: 12616125. PMCID: PMC1514312.

13. Shimamoto K, Satake H, Sawaki A, Ishigaki T, Funahashi H, Imai T. 1998; Preoperative staging of thyroid papillary carcinoma with ultrasonography. Eur J Radiol. 29(1):4–10. DOI: 10.1016/S0720-048X(97)00184-8. PMID: 9934552.

14. Solorzano CC, Carneiro DM, Ramirez M, Lee TM, Irvin GL 3rd. 2004; Surgeon-performed ultrasound in the management of thyroid malignancy. Am Surg. 70(7):576–80. discussion 80–2. DOI: 10.1177/000313480407000703. PMID: 15279178.

15. O'Connell K, Yen TW, Quiroz F, Evans DB, Wang TS. 2013; The utility of routine preoperative cervical ultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer. Surgery. 154(4):697–701. discussionDOI: 10.1016/j.surg.2013.06.040. PMID: 24011674.

16. Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, et al. 2006; Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 141(5):489–94. discussion 94–6. DOI: 10.1001/archsurg.141.5.489. PMID: 16702521.

17. Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, et al. 2007; Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. J Clin Endocrinol Metab. 92(9):3590–4. DOI: 10.1210/jc.2007-0444. PMID: 17609301.

18. Chung SR, Baek JH, Rho YH, Choi YJ, Sung TY, Song DE, et al. 2022; Sonographic diagnosis of cervical lymph node metastasis in patients with thyroid cancer and comparison of European and Korean guidelines for stratifying the risk of malignant lymph node. Korean J Radiol. 23(11):1102–11. DOI: 10.3348/kjr.2022.0358. PMID: 36126955. PMCID: PMC9614289.

19. Lee JY, Yoo RE, Rhim JH, Lee KH, Choi KS, Hwang I, et al. 2022; Validation of ultrasound risk stratification systems for cervical lymph node metastasis in patients with thyroid cancer. Cancers (Basel). 14(9):2106. DOI: 10.3390/cancers14092106. PMID: 35565235. PMCID: PMC9105025.

20. Lee Y, Kim JH, Baek JH, Jung SL, Park SW, Kim J, et al. 2018; Value of CT added to ultrasonography for the diagnosis of lymph node metastasis in patients with thyroid cancer. Head Neck. 40(10):2137–48. DOI: 10.1002/hed.25202. PMID: 29756249.

21. Suh CH, Baek JH, Choi YJ, Lee JH. 2017; Performance of CT in the preoperative diagnosis of cervical lymph node metastasis in patients with papillary thyroid cancer: a systematic review and meta-analysis. AJNR Am J Neuroradiol. 38(1):154–61. DOI: 10.3174/ajnr.A4967. PMID: 27789450. PMCID: PMC7963646.

22. Alabousi M, Alabousi A, Adham S, Pozdnyakov A, Ramadan S, Chaudhari H, et al. 2022; Diagnostic test accuracy of ultrasonography vs computed tomography for papillary thyroid cancer cervical lymph node metastasis: a systematic review and meta- analysis. JAMA Otolaryngol Head Neck Surg. 148(2):107–18. DOI: 10.1001/jamaoto.2021.3387. PMID: 34817554. PMCID: PMC8613701.

23. Jeon SJ, Kim E, Park JS, Son KR, Baek JH, Kim YS, et al. 2009; Diagnostic benefit of thyroglobulin measurement in fine-needle aspiration for diagnosing metastatic cervical lymph nodes from papillary thyroid cancer: correlations with US features. Korean J Radiol. 10(2):106–11. DOI: 10.3348/kjr.2009.10.2.106. PMID: 19270855. PMCID: PMC2651448.

24. Cignarelli M, Ambrosi A, Marino A, Lamacchia O, Campo M, Picca G, et al. 2003; Diagnostic utility of thyroglobulin detection in fine-needle aspiration of cervical cystic metastatic lymph nodes from papillary thyroid cancer with negative cytology. Thyroid. 13(12):1163–7. DOI: 10.1089/10507250360731578. PMID: 14751038.

25. Chung SR, Baek JH, Choi YJ, Sung TY, Song DE, Kim TY, et al. 2021; Diagnostic algorithm for metastatic lymph nodes of differentiated thyroid carcinoma. Cancers (Basel). 13(6):1388. DOI: 10.3390/cancers13061338. PMID: 33809585. PMCID: PMC8000218.

26. Cunha N, Rodrigues F, Curado F, Ilheu O, Cruz C, Naidenov P, et al. 2007; Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. Eur J Endocrinol. 157(1):101–7. DOI: 10.1530/EJE-07-0088. PMID: 17609408.

27. Chung J, Kim EK, Lim H, Son EJ, Yoon JH, Youk JH, et al. 2014; Optimal indication of thyroglobulin measurement in fine- needle aspiration for detecting lateral metastatic lymph nodes in patients with papillary thyroid carcinoma. Head Neck. 36(6):795–801. DOI: 10.1002/hed.23371. PMID: 23616395.

28. Sun J, Li P, Chen X, Yu Q, Li L. 2022; The influence of thyroid status, serum Tg, TSH, and TgAb on FNA-Tg in cervical metastatic lymph nodes of papillary thyroid carcinoma. Laryngoscope Investig Otolaryngol. 7(1):274–82. DOI: 10.1002/lio2.717. PMID: 35155808. PMCID: PMC8823256.

29. Sigstad E, Heilo A, Paus E, Holgersen K, Groholt KK, Jorgensen LH, et al. 2007; The usefulness of detecting thyroglobulin in fine-needle aspirates from patients with neck lesions using a sensitive thyroglobulin assay. Diagn Cytopathol. 35(12):761–7. DOI: 10.1002/dc.20726. PMID: 18008339.

30. Kim MJ, Kim EK, Kim BM, Kwak JY, Lee EJ, Park CS, et al. 2009; Thyroglobulin measurement in fine-needle aspirate washouts: the criteria for neck node dissection for patients with thyroid cancer. Clin Endocrinol (Oxf). 70(1):145–51. DOI: 10.1111/j.1365-2265.2008.03297.x. PMID: 18466347.

31. Moon JH, Kim YI, Lim JA, Choi HS, Cho SW, Kim KW, et al. 2013; Thyroglobulin in washout fluid from lymph node fine- needle aspiration biopsy in papillary thyroid cancer: large-scale validation of the cutoff value to determine malignancy and evaluation of discrepant results. J Clin Endocrinol Metab. 98(3):1061–8. DOI: 10.1210/jc.2012-3291. PMID: 23393171.

32. Duval M, Zanella AB, Cristo AP, Faccin CS, Graudenz MS, Maia AL. 2017; Impact of serum TSH and anti-thyroglobulin antibody levels on lymph node fine-needle aspiration thyroglobulin measurements in differentiated thyroid cancer patients. Eur Thyroid J. 6(6):292–7. DOI: 10.1159/000479682. PMID: 29234622. PMCID: PMC5704678.

33. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. 2008; Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 150(1):49–52. DOI: 10.1016/j.jss.2007.09.020. PMID: 17996901. PMCID: PMC2575056.

34. Suh I, Vriens MR, Guerrero MA, Griffin A, Shen WT, Duh QY, et al. 2010; Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cell neoplasms of the thyroid. Am J Surg. 200(1):41–6. DOI: 10.1016/j.amjsurg.2009.08.030. PMID: 20637335.

35. Lee EK, Chung KW, Min HS, Kim TS, Kim TH, Ryu JS, et al. 2012; Preoperative serum thyroglobulin as a useful predictive marker to differentiate follicular thyroid cancer from benign nodules in indeterminate nodules. J Korean Med Sci. 27(9):1014–8. DOI: 10.3346/jkms.2012.27.9.1014. PMID: 22969246. PMCID: PMC3429817.

36. Youn I, Sung JM, Kim EK, Kwak JY. 2014; Serum thyroglobulin adds no additional value to ultrasonographic features in a thyroid malignancy. Ultrasound Q. 30(4):287–90. DOI: 10.1097/RUQ.0000000000000056. PMID: 25415866.

37. Patell R, Mikhael A, Tabet M, Bena J, Berber E, Nasr C. 2018; Assessing the utility of preoperative serum thyroglobulin in differentiated thyroid cancer: a retrospective cohort study. Endocrine. 61(3):506–10. DOI: 10.1007/s12020-018-1643-z. PMID: 29948933.

38. Kars A, Aktan B, Kilic K, Sakat MS, Gozeler MS, Yoruk O, et al. Preoperative serum thyroglobulin level as a useful predictive marker to differentiate thyroid cancer. ORL J Otorhinolaryngol Relat Spec. 2018; 80(5-6):290–5. DOI: 10.1159/000491932. PMID: 30253396.

39. Wang L, Li H, Yang Z, Guo Z, Zhang Q. 2015; Preoperative serum thyrotropin to thyroglobulin ratio is effective for thyroid nodule evaluation in euthyroid patients. Otolaryngol Head Neck Surg. 153(1):15–9. DOI: 10.1177/0194599815579877. PMID: 25883100.

40. Scheffler P, Forest VI, Leboeuf R, Florea AV, Tamilia M, Sands NB, et al. 2014; Serum thyroglobulin improves the sensitivity of the McGill Thyroid Nodule Score for well-differentiated thyroid cancer. Thyroid. 24(5):852–7. DOI: 10.1089/thy.2013.0191. PMID: 24341425.

41. Huang Z, Song M, Wang S, Huang J, Shi H, Huang Y, et al. 2020; Preoperative serum thyroglobulin is a risk factor of skip metastasis in papillary thyroid carcinoma. Ann Transl Med. 8(6):389. DOI: 10.21037/atm.2019.10.92. PMID: 32355833. PMCID: PMC7186689.

42. Kim H, Kim YN, Kim HI, Park SY, Choe JH, Kim JH, et al. 2017; Preoperative serum thyroglobulin predicts initial distant metastasis in patients with differentiated thyroid cancer. Sci Rep. 7(1):16955. DOI: 10.1038/s41598-017-17176-6. PMID: 29209067. PMCID: PMC5717168.

43. Alhefdhi A, Altayyar T, Alqahtani SM, Alshehri M, Elnaas S, Alsobhi S. 2020; Can preoperative serum thyroglobulin and anti- thyroglobulin levels predict malignant potential of a thyroid nodule with atypia or follicular lesion of undetermined significance? Otorhinolaryngology-Head & Neck Surgery. 5(2):1–4. DOI: 10.15761/OHNS.1000236.

44. Trimboli P, Treglia G, Giovanella L. 2015; Preoperative measurement of serum thyroglobulin to predict malignancy in thyroid nodules: a systematic review. Horm Metab Res. 47(4):247–52. DOI: 10.1055/s-0034-1395517. PMID: 25384015.

45. Alhozali A. 2022; Prevalence and clinical significance of preoperative thyroglobulin antibodies in differentiated thyroid cancer patients. Open J Endocr Metab Dis. 12(11):238–250. DOI: 10.4236/ojemd.2022.1211018.

46. Jia X, Pang P, Wang L, Zhao L, Jiang L, Song Y, et al. 2020; Clinical analysis of preoperative anti-thyroglobulin antibody in papillary thyroid cancer between 2011 and 2015 in Beijing, China: a retrospective study. Front Endocrinol (Lausanne). 11:452. DOI: 10.3389/fendo.2020.00452. PMID: 32760349. PMCID: PMC7373730.

47. Chen Z, Lin Y, Lai S, Wang P, Li J, Wang L, et al. 2022; The utility of serum anti-thyroglobulin antibody and thyroglobulin in the preoperative differential diagnosis of thyroid follicular neoplasms. Endocrine. 76(2):369–76. DOI: 10.1007/s12020-022-02993-1. PMID: 35112214.

48. Kaynak H, KocavaŞ M, Can M, Çordan I, Karaköse M, Karakurt F, et al. 2023; The relationship between pre-operative anti-thyroglobulin antibody level and lymph node metastasis and recurrence in differentiated thyroid cancer. Turk J Oncol. 38(1):29–35.

49. Jo K, Kim MH, Ha J, Lim Y, Lee S, Bae JS, et al. 2017; Prognostic value of preoperative anti-thyroglobulin antibody in differentiated thyroid cancer. Clin Endocrinol (Oxf). 87(3):292–9. DOI: 10.1111/cen.13367. PMID: 28493284.

50. Shuai JH, Leng ZF, Wang P, Ji YC. 2023; Correlation analysis of serum thyroglobulin, thyroid-stimulating hormone levels, and thyroid-cancer risk in thyroid nodule surgery. World J Clin Cases. 11(27):6407–14. DOI: 10.12998/wjcc.v11.i27.6407. PMID: 37900235. PMCID: PMC10600984.

51. Li S, Ren C, Gong Y, Ye F, Tang Y, Xu J, et al. 2022; The role of thyroglobulin in preoperative and postoperative evaluation of patients with differentiated thyroid cancer. Front Endocrinol (Lausanne). 13:872527. DOI: 10.3389/fendo.2022.872527. PMID: 35721746. PMCID: PMC9200986.

52. Petric R, Besic H, Besic N. 2014; Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small follicular and Hurthle cell neoplasms of the thyroid gland. World J Surg Oncol. 12:282. DOI: 10.1186/1477-7819-12-282. PMID: 25213012. PMCID: PMC4168052.

53. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, et al. 2006; Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 91(2):498–505. DOI: 10.1210/jc.2005-1534. PMID: 16303836.

54. Rosenbaum-Krumme SJ, Gorges R, Bockisch A, Binse I. 2012; 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur J Nucl Med Mol Imaging. 39(9):1373–80. DOI: 10.1007/s00259-012-2065-4. PMID: 22718304.

55. Qiu ZL, Xue YL, Song HJ, Luo QY. 2012; Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Nucl Med Commun. 33(12):1232–42. DOI: 10.1097/MNM.0b013e328358d9c0. PMID: 23111353.

56. Hong CM, Ahn BC, Jeong SY, Lee SW, Lee J. 2013; Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake. Nuklearmedizin. 52(4):121–9. DOI: 10.3413/Nukmed-0541-12-11. PMID: 23928981.

57. Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, et al. 2011; Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr Relat Cancer. 18(1):159–69. DOI: 10.1677/ERC-10-0233. PMID: 21118976.

58. Treglia G, Annunziata S, Muoio B, Salvatori M, Ceriani L, Giovanella L. 2013; The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: an overview. Int J Endocrinol. 2013:856189. DOI: 10.1155/2013/856189. PMID: 23653645. PMCID: PMC3638656.

59. Zampella E, Klain M, Pace L, Cuocolo A. 2021; PET/CT in the management of differentiated thyroid cancer. Diagn Interv Imaging. 102(9):515–23. DOI: 10.1016/j.diii.2021.04.004. PMID: 33926848.

60. Cracolici V. 2023; No longer well-differentiated: diagnostic criteria and clinical importance of poorly differentiated/high-grade thyroid carcinoma. Surg Pathol Clin. 16(1):45–56. DOI: 10.1016/j.path.2022.09.006. PMID: 36739166.

61. Vadrucci M, Serio G, Baroli A. 2016; 18F-FDG PET/CT-guided clinical management of the rare aggressive "columnar-cell" variant of papillary thyroid cancer. Endocrinol Metab (Seoul). 31(2):343–4. DOI: 10.3803/EnM.2016.31.2.343. PMID: 27184016. PMCID: PMC4923420.

62. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, et al. 2015; Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Thyroid. 25(4):437–44. DOI: 10.1089/thy.2014.0320. PMID: 25633259.

63. Kim K, Shim SR, Lee SW, Kim SJ. 2021; Diagnostic values of F-18 FDG PET or PET/CT, CT, and US for preoperative lymph node staging in thyroid cancer: a network meta-analysis. Br J Radiol. 94(1120):20201076. DOI: 10.1259/bjr.20201076. PMID: 33595337. PMCID: PMC8010543.

64. Lee CH, Lee SW, Son SH, Hong CM, Jeong JH, Jeong SY, et al. 2019; Prognostic value of lymph node uptake on pretreatment F-18 FDG PET/CT in patients with N1b papillary thyroid carcinoma. Endocr Pract. 25(8):787–93. DOI: 10.4158/EP-2018-0607. PMID: 31013158.